



# THE WEINBERG GROUP®

## NICHOLAS M. FLEISCHER, R.PH., PH.D.

Vice President

P +1 202.730.4131

[nick.fleischer@weinberggroup.com](mailto:nick.fleischer@weinberggroup.com)

### EDUCATION

- 1991 Ph.D., Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD
- 1978 M.S., Hospital Pharmacy Administration, Arnold and Marie Schwartz College of Pharmacy of Long Island University, Brooklyn, NY
- 1972 B.S., Pharmacy, Massachusetts College of Pharmacy, Boston, MA

### EXPERIENCE

Dr. Nicholas Fleischer is a Vice President at The Weinberg Group. He has extensive experience in biopharmaceutics, pharmacokinetics, and clinical pharmacy. Prior to joining The Weinberg Group, Dr. Fleischer held several positions at the United States Food and Drug Administration (FDA), the most recent being Director of the Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research (CDER). At CDER, he was also Director of the Division of Pharmaceutical Evaluation III, Office of Clinical Pharmacology and Biopharmaceutics, Chief of the Pharmacokinetics Evaluation Branch I, Division of Biopharmaceutics, Deputy Director in the Office of Generic Drugs, and Acting Section Head in the Anti-Infective Group, Division of Biopharmaceutics. In the Division of Biopharmaceutics, he also served as Acting Branch Chief for the Scientific Support Branch, Acting Section Head for the Rapid Resolution Team, pharmacokinetic reviewer, and Special Assistant to the Acting Director. He served for 2 years as a biopharmaceutical analyst at the National Center for Drugs and Biologics.

Prior to joining the FDA, Dr. Fleischer was Deputy Chief, Assistant Chief, and Director of Quality Control in the Pharmacy Department of the U.S. Public Health Service Hospital, Staten Island, NY. Dr. Fleischer is a registered pharmacist and maintains active pharmacist licenses in Massachusetts and Maryland. Dr. Fleischer serves on the editorial board of the Journal of Generic Medicines. Dr. Fleischer's experience at The Weinberg Group includes:

#### Strategic, Drug Development, and Regulatory Support

- Providing evaluation and analysis of product development plans for pharmaceuticals and biologics, and providing strategic direction based on regulatory, scientific, and marketing issues.
- Contributing to or directing due diligence evaluations for potential acquisitions, including consideration of scientific data and possible regulatory strategies.

- Evaluating and providing advice to clients on adequacy of draft regulatory submissions; managing revisions of pharmacology, clinical, toxicology, and manufacturing sections, as needed.
- Providing scientific and strategic support to clients in resolving product effectiveness and/or safety issues, including thorough review and critical analysis of the published literature pertaining to the drug class.
- Analyzing pharmacokinetic and bioequivalence data and preparing reports for regulatory submissions.

### **Litigation Support**

- Serving as an expert witness in generic drug and pharmaceutical patent infringement litigation.

Prior to joining The Weinberg Group, Dr. Fleischer's FDA experience included the following:

#### **FDA, CDER, Division of Bioequivalence, Office of Generic Drugs**

Director

Responsible for an international program to assure that generic drugs were bioequivalent to the brand name products. Directed approximately 24 doctoral level scientists in the review of the bioequivalence section of generic drug applications. Established sound scientific principles and promoted their application in a consistent and fair manner. Developed and contributed to drug-specific and general guidelines for the pharmaceutical industry, including SUPAC-SS Nonsterile Semisolid Dosage Forms Scale-up and Postapproval Change: Chemistry, Manufacturing, and Controls; *In Vitro* Release Testing and *In Vivo* Bioequivalence Documentation.

#### **FDA, CDER, Division of Pharmaceutical Evaluation III, Office of Clinical Pharmacology and Biopharmaceutics**

Director

Responsible for supervising the review of the human pharmacokinetics and bioavailability section of New Drug Applications (NDAs) and pharmacokinetic/biopharmaceutic data in Investigational New Drug Applications (INDs). The first three anti-HIV protease inhibitor drugs were reviewed and approved under his directorship. Dr. Fleischer served as the first chairman of the Biopharmaceutics Coordinating Committee and chaired the Therapeutics Inequivalence Action Coordinating Committee. He contributed to the development of the following guidances:

- Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (I).
- Dissolution Testing of Immediate Release Solid Oral Dosage Forms.
- Extended-Release Solid Oral Dosage Forms and Development, Evaluation, and Application of In Vitro-In Vivo Correlations.



## **SIGNIFICANT REVIEW ACTIVITIES**

- Identified potential polymorphic metabolism of omeprazole, first proton-pump inhibitor.
- Uncovered problems with Bolar's generic version of Dyazide, which led to major recall and legal action against Bolar and subsequent Congressional investigation of FDA's generic drug approval process.
- Developed market-wide remedial plan to prevent moisture-related decrease in bioavailability of carbamazepine tablets.

## **PROFESSIONAL AFFILIATIONS**

American Association of Pharmaceutical Scientists (AAPS)

AAPS Workshop on Bioequivalence of Topical Dermatological Dosage Forms Planning Committee

AAPS Workshop on Chemistry and Pharmacy Considerations during the Drug Development and Review Process: Challenges and New Initiatives Planning Committee

American Society for Clinical Pharmacology and Therapeutics (ASCPT)

Commissioned Officers Association of the USPHS

Massachusetts College of Pharmacy Alumni Association

Military Officers Association of America

Rho Chi Pharmaceutical Honor Society

## **HONORS AND AWARDS**

Center for Drug Evaluation and Research Special Recognition Award, 5 June 1998 (2 awards)

Meritorious Service Medal, U.S. Public Health Service, 30 May 1991

Graduate Student Grant for Research, USUHS, November 1987 and November 1986

Emma L. Bockman Award, USUHS, 13 May 1987

Unit Commendation, U.S. Public Health Service, 29 September 1981

Achievement Medal, U.S. Public Health Service, 12 August 1981

## **LANGUAGES**

Fluent in Hungarian

## **PRESENTATIONS**

Fleischer NM. 2011. ANDA vs. 505(b)(2)- When and why. A webinar presented by The Weinberg Group Inc.; 21 Dec; Washington, DC.

Fleischer NM, Roth RI. 2011. Important Lessons in Developing Biosimilars. A webinar presented by The Weinberg Group Inc.; 28 Sep; Washington, DC.



Fleischer NM, Falk JI. 2009. ANDA vs. 505(b)(2)- When and why. A webinar presented by The Weinberg Group Inc.; 30 Sep; Washington, DC.

Fleischer NM, Cooper P, Roth RI. 2009 Global lessons in developing biosimilars. A webinar presented by The Weinberg Group Inc.; 27 May; Washington, DC.

Fleischer NM. 2008. Generic carve-outs. Presented at: The Pharmaceutical Care Management Association State Health Affairs Committee Meeting; 9 Jan; Alexandria, VA.

Fleischer NM. 2007. FDA's 505(b)(2) NDA process – a key avenue to approval for drug delivery technologies. Presented at: The 12th Annual Drug Delivery Technologies & Deal Making conference; 26 Sep; New Brunswick, NJ.

Fleischer NM. 2007. 505(b)(2): risks and rewards of generic innovation. Presented at: The 8<sup>th</sup> Annual Generic Drugs Summit on Strategic Planning for Growth in the Competitive Generics Marketplace; 19 Sep; Washington, DC.

Fleischer NM. 2006. Evaluating the present position on generic biologics. Panel presentation at: The New York Biotechnology Association Annual Meeting; 18 Apr; New York, NY.

Holford N, Fleischer NM, Peck C. 2005. Topical corticosteroid bioequivalence – an evaluation of the FDA guidance. Poster Presented at: The 14<sup>th</sup> Meeting of the Population Approach Group in Europe; 17 Jun; Pamplona, Spain.

Fleischer NM. 2004. Biopharmaceutics overview and FDA standards for bioequivalence. Presented at: The Project Management Group of Sandoz Pharmaceuticals; 16 Jan; Dayton, NJ.

Fleischer NM. 2003. Biopharmaceutics overview and FDA standards for bioequivalence. Presented at: The Formulations Development Group of Geneva Pharmaceuticals; 31 Oct; Dayton, NJ.

Fleischer NM. 2003. Drug delivery technology – an avenue for bioequivalence. Presented at: The Marcus Evans Generic Drugs Forum conference; 29 Jul; Philadelphia, PA.

Fleischer NM. 2003. The impact of new and pending FDA guidances on the pharmaceutical industry. Presented at: The SFBC Fort Myers Scientific Symposium; 25 Apr; Fort Myers, FL.

Fleischer NM. 2001. Evaluating the present position on generic biologics. Presented at: The Institute for International Research meeting on Preparing for Successful Submissions & Understanding the Legal Challenges to Expedite Market Entry; 4 Dec; McLean, VA.

Fleischer NM. 1999. For which drug products is a multiple-dose bioequivalence study necessary. Presented at: The Institute for International Research meeting on Establishing Bioequivalence - Speeding Development and Meeting Regulatory Requirements; 18 Jun; Philadelphia, PA.

Fleischer NM. 1999. International regulatory guidelines: where we have been and where we are Going. Presented at: The Institute for International Research meeting on Establishing



Bioequivalence - Speeding Development and Meeting Regulatory Requirements; 17 Jun; Philadelphia, PA.

Fleischer NM. 1998. Generic drugs and intellectual property rights in the global pharmaceutical market - FDA perspectives. Presented at: The Fourth European Congress of Pharmaceutical Sciences; 11 Sep; Milan, Italy.

Fleischer NM. 1998. What will the requirements for individual bioequivalence studies mean for generic registrations in Europe. Presented at: The Institute for International Research conference on Achieving Successful Generic Product Registration under the New System in Europe; 14 Jul and 2 Apr; London, England.

Fleischer NM. 1998. Utilizing bioequivalence study requirements to speed-up Development and FDA Approval. Presented at: The Institute for International Research conference on Generics - Marketing, Compliance & Procurement Strategies to Maximize Your Competitive Edge; 26 Feb; Orlando, FL.

Fleischer NM. 1997. Update on Streamlining bioequivalence review process, database for bio-reviews. Presented at: The 1997 Mid-Year Meeting and Educational Conference of the National Association of Pharmaceutical Manufacturers; 23 Jun; Washington, DC.

Fleischer NM. 1997. Division of bioequivalence perspectives. Presented at: The 1997 Generic Pharmaceutical Industry Association Annual Meeting; 10 Mar; Miami, FL.

Fleischer NM. 1997. Initiatives for division of bioequivalence. Presented at: The 1997 National Association of Pharmaceutical Manufacturers Annual Meeting; 31 Jan; Naples, FL.

Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM., et al. 1996. Bioequivalence of topical dermatological dosage forms – methods of evaluation of bioequivalence. Presented at: The AAPS/FDA Workshop on Bioequivalence of Topical Dermatological Dosage Forms; 4-6 Sep; Bethesda, MD.

Fleischer NM. 1996. Regulatory perspectives of product line extensions. Presented at: The AAPS Midwest Regional Meeting; 20 May; Chicago, IL.

Fleischer NM. 1994. Penetration enhancers – Current status, regulatory and safety aspects. Presented at: The AAPS Ninth Annual Meeting and Exposition; 8 Nov; San Diego, CA.

Fleischer NM. 1993. Biopharmaceutics perspectives in drug development. Presented at: The AAPS Workshop on Chemistry and Pharmacy Considerations during the Drug Development and Review Process: Challenges and New Initiatives; 23 Sep; Arlington, VA.

Fleischer NM. 1990. Generic drugs: changes being implemented. Presented at: The 86th Annual Meeting of the National Association of Boards of Pharmacy; 20 May; Phoenix, AZ.

Fleischer NM. 1990. Safety and efficacy in the generic drug industry. Presented at: The Annual Conference of the National Council for Prescription Drug Programs; 15 Feb; Scottsdale, AZ.



Fleischer NM. 1989. FDA commentary on drug metabolism section of NDA. Presented at: The Drug Development Workshop of the Regulatory Affairs Professionals Society; 13 Jun; Bethesda, MD.

Fleischer NM. 1989. New programs in the division of biopharmaceutics. Presented at: The 28th Annual International Industrial Pharmacy Conference; 2 Jun; Austin, TX.

Fleischer NM. 1989. Importance of pharmacokinetics/pharmacodynamics in the drug development process. Presented at: The PMA R&D/Medical Section Annual Meeting; 12 Apr; Laguna Niguel, CA.

Fleischer NM, Peck C. 1988. Utilization of physiologic pharmacokinetic modeling to evaluate the transdermal efflux of isoflurane. Presented at: The Second Annual Symposium Frontiers of Pharmacokinetics and Pharmacodynamics; 12-14 Oct; Little Rock, AR.

Fleischer NM. 1986. Disposition and transdermal collection of isoflurane. Presented at: The Graduate Research Colloquium, USUHS; 14 May; Bethesda, MD, and at the Department of Pharmacology Seminar, USUHS; 6 May; Bethesda, MD.

Zelonis A, Fleischer NM, Walling R. 1978. A pharmacy quality assurance program. Presented by A. Zelonis at: The USPHS Professional Association Meeting; 28 Mar; Atlanta, GA.

Fleischer NM, Zelonis A. 1977. Pharmacist involvement at an oncology clinic. Presented by A. Zelonis at: The USPHS Professional Association Meeting; 6 Apr; San Francisco, CA.

Fleischer NM. 1975. Improved utilization of pharmacy manpower, by N. Fleischer. Presented (by title only) at: The USPHS Professional Association Meeting; 2-5 Jun; Las Vegas, NV.

Fleischer NM. 1974. Quality control for microbial contamination in a hospital pharmacy. Presented at: The USPHS Professional Association Meeting; 9 Apr; Washington, DC.

Fleischer NM. 1973. Invited speaker on 'Pharmacy as a profession.' Egbert Junior High School; April; Staten Island, NY.

## **PUBLICATIONS**

Fleischer NM, Roth RI. 2009. A follow-on biological drug is not a biogeneric: lessons from Omnitrope and Valtropin. *Journal of Generic Medicines*. 6:237-245.

Fleischer NM, Roth RI. 2005. Scientific issues for biogenerics/biosimilars. *Journal of Generic Medicines*. 2(2):125-132.

Fleischer NM, Roth RI. 2002. Gene therapy; applications to pharmacy practice. *J Am Pharm Assoc*. 42(5):692-698.



Fleischer NM, Perry R. 2002. Report on the U.S. draft guidance for food effect and bioavailability studies. Regul Aff J. 13(8):649-651.

Falk JI, Fleischer NM. 1998. FDA modernization efforts. Regul Aff J. 7:469-471.



Shah VP, Flynn GL, Yacobi A, et al. 1998. Bioequivalence of topical dermatological dosage forms - methods of evaluation of bioequivalence, AAPS/FDA workshop on 'bioequivalence of topical dermatological dosage forms – methods of evaluating bioequivalence,' September 4-6, 1996, Bethesda, MD. *Skin Pharmacol Appl Skin Physiol.* 11(2):117-24.

Shah V, Flynn G, Yacobi A, et al. 1998. AAPS/FDA workshop report; bioequivalence of topical dermatological dosage forms -- methods of evaluation of bioequivalence. *Pharm Res.* 15(2):167-171.

Singh GJ, Fleischer NM, Lesko L, Williams R. 1998. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. *Pharm Res.* 15(1):4-7.

Malinowski H, Marroum P, Uppoor UR, et al. 1997. Draft guidance for industry, extended-release solid oral dosage forms and development, evaluation, and application of *in vitro-in vivo* correlations. *Adv Exp Med Biol.* 423:269-288.

Zelonis A, Fleischer NM, Walling R. 1979. A pharmacy quality assurance program. *Hosp Formul.* 14(2):205-211.

Fleischer NM. 1973. Promethazine hydrochloride-morphine sulfate incompatibility. *Am J Hosp Pharm.* 30(8):665.

## ABSTRACTS

Holford N, Fleischer NM, Peck C. 2005. Topical corticosteroid bioequivalence – an evaluation of the FDA guidance. Poster presented at: The 2005 PAGE (Population Approach Group Europe) Annual Meeting; 16-17 Jun; Pamplona, Spain.

Fleischer NM. 2001. Clinical pharmacology perspectives of recent FDA bioequivalence decisions. Poster presented at: The 2001 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 6-10 April; Orlando, FL. (Abstract published in *Clin. Pharm. Ther.* 69(2):P36).

Fleischer NM. 1998. Bioequivalence - past, present and future. *European Journal of Pharmaceutical Sciences.* 6/Suppl.1:S98.

Conner D, Roizen M, Fleischer NM, Almirez R, Peck C. 1989. Transcutaneous chemical collection of Isoflurane in surgical patients. Poster presented at: The International Conference on Prediction of Percutaneous Penetration; 4-6 Apr; Manchester, United Kingdom. (Abstract published in *Pharmacotherapy* 9(3):777).

Fleischer NM, Peck C. 1988. Formulation of the gaseous anesthetic Isoflurane for intravenous injection. Poster presented at: The NIH/ADAMHA-Industry Collaboration Forum; 25 October; Washington, DC; the FDA Science Poster Exposition; 27-28 Apr; Rockville, MD; and the Annual Meeting of the American Association of Pharmaceutical Scientists; 2 Nov 1986; Washington, DC. (Abstract published in *Pharmaceutical Research* 3(5):91S, 1986).



Fleischer NM, Peck C, et al. 1988. Reduced cutaneous blood flow affects transdermal chemical migration. Poster presented at: The FDA Science Poster Exposition; 27-28 Apr; Rockville, MD; and at the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics; 9-11 Mar; San Diego, CA. (Abstract published in *Clin. Pharm. Ther.* 43(2):137, 1986).

Fleischer NM, Peck C. 1988. The transdermal collection of intravenously administered Isoflurane. Poster presented at: The FDA Science Poster Exposition; 27-28 Apr; Rockville, MD; and the Graduate Research Colloquium of the Uniformed Services University of the Health Sciences; 13 May 1987; Bethesda, MD. Also presented at the Department of Pharmacology Seminar, USUHS; 28 Apr 1987, and the Graduate Student Symposium of the DC Section, Society for Experimental Biology and Medicine; 25 Mar; Bethesda, MD. (Abstract published in *Proc. Soc. Exp. Biol. Med.* 188(1):115, 1988).

Fleischer NM, Peck C, et al. 1988. The pharmacokinetics of intravenously administered Isoflurane in the rat. Poster at the FDA Science Poster Exposition; 27-28 Apr; Rockville, MD; and The Annual Meeting of the American Association of Pharmaceutical Scientists; 2-6 Nov 1986; Washington, DC. (Abstract published in *Pharmaceutical Research* 3(5):165S, 1986).

Peck C, Conner D, Fleischer NM, et al. 1987. Physiologically based pharmacokinetic modeling of noninvasive transcutaneous chemical dosimetry. Presented by N. Fleischer, at: The Hanford Life Sciences Symposium; 20-23 Oct; Richland, WA. (Abstract published in *Health Physics*. 57(Suppl.):157, 1989).

## TEACHING

Fleischer NM. 2009. The New Drug Approval process: NDA submission and review. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: A Program on Understanding How the Drug Industry is Regulated; 5 November; Washington, DC.

Fleischer NM. 2008. The New Drug Approval process: NDA submission and review. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: A Program on Understanding How the Drug Industry is Regulated; 20 November; Washington, DC.

Fleischer NM. 2008. The New Drug Approval process: NDA submission and review. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: A Program on Understanding How the Drug Industry is Regulated; 21 February; Washington, DC.

Fleischer NM. 2007. The practical and legal perspective of bioequivalence. Continuing Medical Education Program at <http://www.cmediscussions.com/7155/>; Released 12 October.

Fleischer NM. 2006. The Abbreviated NDA (ANDA), 505(b)(2) applications, and patent exclusivity issues. Presented at the Food and Drug Law Institute's Workshop on Introduction to Drug Law and Regulation: Understanding How the FDA Regulates the Drug Industry; 6 November; Washington, DC.



Fleischer NM. 2005. The New Drug Approval process: NDA submission and review. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: Understanding How the FDA Regulates the Drug Industry; 17 November; Washington, DC.

Fleischer NM. 2005. Bioequivalence of generic drugs – does therapeutic equivalence follow? Presented at the Clinical Pharmacology Academic Conference, National Naval Medical Center; 29 March; Bethesda, MD.

Fleischer NM. 2004. The full NDA. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: Understanding How the FDA Regulates the Drug Industry; 4 November; Washington, DC.

Fleischer NM. 2003. The full NDA. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: Understanding How the FDA Regulates the Drug Industry; 17 November; Washington, DC.

Fleischer NM. 2002. Post-approval submission requirements. Presented at the Regulatory Affairs Professional Society NDA Workshop; 8 November; Philadelphia, PA.

Fleischer NM. 2002. The full NDA. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: Understanding How the FDA Regulates the Drug Industry; 4 November; Washington, DC.

Fleischer NM. 2001. The full NDA. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: Understanding How the FDA Regulates the Drug Industry; 8 November; Washington, DC.

Fleischer NM. 2000. The full NDA. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: Understanding How the FDA Regulates the Drug Industry; 14 September; Washington, DC.

Fleischer NM. 2000. International regulatory systems: operating in a global market - ICH, FDA initiatives, reality. Presented at the Food and Drug Law Institute's 2000 Summer Internship Program; 21 June; Washington, DC.

Fleischer NM. 1999. The full NDA. Presented at the Food and Drug Law Institute Workshop on Introduction to Drug Law and Regulation: Understanding How FDA Regulates the Drug Industry; 4 November; Washington, DC.

Fleischer NM. 1998. Marketing exclusivity: selected current issues facing generic and innovator drug companies - scientific perspectives. Presented at the Food and Drug Law Institute's 42<sup>nd</sup> Annual Education Conference; 17 December; Washington, DC.

Fleischer NM. 1998. The full NDA. Presented at the Food and Drug Law Institute Course on Introduction to Drug Law and Regulation; 5 November; Washington, DC.



Fleischer NM. 1998. (initial appointment, 1993). Adjunct Associate Professor, Department of Pharmacology, Division of Clinical Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD.

Fleischer NM. 1997. The "New Drug" Approval requirement. Presented at the Food and Drug Law Institute Course on Introduction to Drug Law and Regulation; 27 October; Washington, DC.

Fleischer NM. 1997. Career options for Ph.Ds. Presented at York College, CUNY; 29 September; Queens, NY.

Fleischer NM. 1990. Decisions in the approval process for ANDA's. Presented at the Advanced New Drug Approval Training for Analysts; 27 September; Philadelphia, PA.

Fleischer NM. 1990. Monitoring generic drugs: an FDA update and perspective. Presented at the 35th Annual Ohio Pharmaceutical Seminar; 18 April; Columbus, OH.

Fleischer NM. 1989. Biopharmaceutical issues. Presented at the Continuing Education Seminar for Federal Pharmacists; 9 December; Bethesda, MD.

Fleischer NM. 1989. MK-Model: A Demonstration. Presented at Division of Biopharmaceutics Scientific Rounds; 3 February; Rockville, MD.

Fleischer NM. 1979. Invited lecturer on "Pharmacy practice in the USPHS and career opportunities," Rutgers College of Pharmacy; December 1979 and November 1980; Piscataway, NJ.

Fleischer NM. 1979. Invited lecturer on "Pharmacists in the federal government," Rutgers College of Pharmacy; March 1979; Piscataway, NJ.

Fleischer NM. 1977. Invited lecturer on "Aseptic technique in intravenous additive manufacture and incompatibilities," USPHS Hospital Medical Intensive Care Unit Course for Nurses; January 1979 and March 1977.

Fleischer NM. 1977 and 1973. Invited lecturer for Pharmacology, Physician Assistant Training Program, USPHS Hospital; Staten Island, NY.

Fleischer NM. 1974. Invited lecturer for Pharmaceutical Calculations, Physician Assistant Training Program, USPHS Hospital; Staten Island, NY.

